



A message from Magnus

Dear friends,

It's almost May already. How did that happen?! It has been an intense, yet fulfilling, start to the year, despite the challenges we are all still facing with the Covid-19 pandemic.

In recent months, the BioVentureHub (BVH) team has been sharing learnings, insights and inspiration to help develop a number of other important collaboration initiatives aimed at bringing people together and driving growth through innovation.

We are very proud to be playing our part to support the bold and powerful steps that are being taken to build [GoCo Health Innovation City](#) around AstraZeneca's global R&D site in Gothenburg. In connection with the 'virtual' groundbreaking of the new Collaboration House on the GoCo campus, Sir Mene Pangalos referenced the BioVentureHub in [an article on co-creating innovation in Sweden](#). We share Mene's view that "we have a lot to look forward to in life sciences in Gothenburg and Sweden in the years ahead, and, most important, in our collective ability to deliver for patients."

Along those lines and alongside AstraZeneca, we are actively engaged in [Health Innovation West](#), an 'umbrella' organisation that aims to harness the combined power of industry, academia and the healthcare sector in West Sweden to attract life science investment, innovation and expertise, and build new structures for collaboration in Sweden and beyond.

Internally at AstraZeneca, we are taking a leading role in the newly-formed [A.Catalyst Network](#)*, an interconnected global network of more than 20 AstraZeneca health innovation hubs that aims to catalyse the development of new solutions to support patients.

We are also super excited about the cross-functional, [AstraZeneca Reference Team \(ART\)](#)* we have created for the BioVentureHub. ART consists of senior colleagues from across AstraZeneca (AZ) functions. The aim of the reference team will be to help us maximise value for AZ by identifying and facilitating collaborative innovation opportunities between AZ and current/future BVH companies/research groups.

A BIG THANK YOU and shout out to the eminent AstraZeneca colleagues who have agreed to be part of ART.

If you want to learn more about any of these initiatives, please feel free to reach out to any of us in the BioVentureHub team.

Kromnigon joins the BioVentureHub

[Kromnigon](#), a Swedish biotech company developing imaging technology to expand multicolour, immunofluorescence microscopy capabilities, has joined the BioVentureHub. We're looking forward to working with Per and the Kromnigon team to help them accelerate the growth of their imaging innovations and to facilitate mutually beneficial scientific interactions between Kromnigon and AstraZeneca/BioVentureHub company scientists.

There are currently 31 companies and 1 academic research group in the BioVentureHub

...and there's more....

- The BioVentureHub featured in [Labiotech's list of the 25 best biotech incubators](#) hatching startup stars in Europe.
- [In an interview with The Analytical Scientist](#), AstraZeneca scientist, Michael Kurczy, referenced the BioVentureHub as an open innovation framework that facilitates industry-academia collaboration at the AstraZeneca Gothenburg site.
- The BioVentureHub joined forces with IBM Sweden and BioVentureHub company, OnDosis, to deliver [a session on sector convergence](#) at Nordic Life Science Days.
- CBS Insights included the BioVentureHub in its [list of corporate innovation labs](#) that are developing solutions to the biggest problems in healthcare.
- In collaboration with Randstad Sweden and Randstad RiseSmart Sverige, [the BioVentureHub hosted a webinar](#) for BVH companies on "how to increase the efficiency of a team."

Six Q1 2021 updates from the BioVentureHub companies/research groups...

- [Cline Scientific](#) entered into a collaboration with AstraZeneca with the aim of uncovering core mechanisms of vascular disease.
- Unique data on [Antaros Medical's](#) proprietary GIP-receptor PET ligand was published in Diabetes.
- [Alzinova](#) announced an Alzheimer's disease biomarker collaboration with Sahlgrenska University Hospital.
- [Emotra](#) has signed a letter of intent with the Japanese company, Beauty Life Corporation, looking at opportunities in Japan.
- [Metabogen](#) reached a new milestone in its development of novel probiotic products with ethics committee approval to start a new clinical study.
- [OnDosis](#) continues to grow and announced a new digital tool collaboration, as well as international recognition for its innovative dosing solution.

Thank you so much for your continued support and encouragement. It is sincerely appreciated.

For more information about the BioVentureHub, please see the [BioVentureHub website](#) and follow us on [LinkedIn](#) and [Workplace \(AstraZeneca employees only\)](#).

Take care and stay healthy!

Magnus

Magnus Björsne

CEO, AstraZeneca BioVentureHub

* Internal AstraZeneca link. Only accessible for AstraZeneca employees.

Copyright © 2021 AstraZeneca all rights reserved.